Objectives: Elderly patients with type 2 diabetes is increasing and sarcopenia is becoming an important problem. Nutrition is important to protect sarcopenia. However, the relationship between energy intake and sarcopenia in elderly patients with diabetes has been unclear.

Research Design and Methods: In this cross-sectional study of 316 patients (181 men and 135 women), we investigated the relationship between nutrient intake and sarcopenia. Nutrient intake was evaluated by the brief-type self-administered diet history questionnaire and body composition was evaluated by bioimpedance analysis. Sarcopenia was defined as having both grip strength of <26kg for men and <18kg for women, and skeletal muscle mass index of <7.0kg/m2 for men and <5.7kg/m2 for women.

Results: Patients with sarcopenia were aged and lower BMI than those without. In addition, energy intake of patients with sarcopenia was lower than that without (Table). Energy intake (per 100 kcal/day) was negatively associated with the presence of sarcopenia (OR: 0.86, 95% CI 0.75-0.99, p=0.041), whereas protein intake (g/kg body weight/day) was not associated with the presence of sarcopenia (1.32, 0.39-4.44, p=0.658) after adjusting for age, sex, exercise, smoking, HbA1c and BMI category.

Conclusion: Energy intake was negatively associated with the presence of sarcopenia in elderly patients with type 2 diabetes.


T. Okamura: None. Y. Hashimoto: Research Support; Self; Asahi Kasei Corporation, Fuji Foundation for Protein Research, Japan Society for the Promotion of Science, MSD K.K.. R. Sakai: None. E. Ushigome: Research Support; Self; Grant-in-Aid for Young Scientists (B), AstraZeneca, Daiichi Sankyo Company, Limited, Novo Nordisk Foundation, Ono Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd.. M. Hamaguchi: None. M. Yamazaki: None. M. Fukui: Research Support; Self; Grant-in-Aid for Scientific Research (C), Ono Pharmaceutical Co., Ltd., AstraZeneca, Astellas Pharma US, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Company, Kyowa Hakko Kirin Co., Ltd., Kissei Pharmaceutical Co., Ltd., MSD K.K., Novo Nordisk Foundation.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.